Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Healios KK Ord Shs HLOSF

Healthcare Biotechnology
Healios KK is a Japan-based company mainly engaged in business in the somatic stem cell regenerative medicine field and in the iPSC regenerative medicine field, which involves research, development and manufacture of regenerative medicine products (iPSC regenerative medicines) utilizing technologies related to induced pluripotent stem cells (iPS cells, iPSCs). The somatic stem cell regenerative medicine field develops and markets cell therapy drugs for acute stroke and acute respiratory distress syndrome using MultiStem, a somatic stem cell product for which the Company holds patent and patent licensing rights. The iPSC regenerative medicines include the creation of universal donor cells (UD), next-generation iPSCs that reduce the risk of immune rejection regardless of human leukocyte antigen (HLA) type using gene editing technology.


PINL:HLOSF - Post by User

Healios KK Ord Shs
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Post by ama21968on Nov 02, 2010 9:34pm
260 Views
Post# 17648497

Rumors:Show your cards and save!!!

Rumors:Show your cards and save!!!

Next round news releases is underway... with all positive and exciting news out and at same time ( in same NR ), Halo is going to announce another PP which is anticipated at much higher price than 40's. Management is working closely with First Captial Co. in market place to get it done before the end of 2010.

I think it does make sense, Halo needs more capital to move forward... there are so many targets..Sherridon ........
Bob ; outside Cold & Lost ; Jungle JV; ....New N43-101; Permiting in next 6 months .. Production in late 2011 or early 2012,,,,,,

Also, with higher priced PP, market makers can manipulate/keep  SP trade at certain higher level... otherwise you gonna see sell off at news which happend very often in Venture market.... 

Sold 15% of my PNP and im in this at higher 20's month ago .... and waiting ....

Do you DD and GLTA 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities